Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis
JournalHepatology (Baltimore, Md.)
MetadataShow full item record
AbstractBackground and Aims: Several recent studies have reported an abnormal liver chemistry profile among patients with coronavirus disease 2019 (COVID-19), although its clinical significance remains unknown. Approach and Results: This systematic review and meta-analysis identified six studies of 586 patients delineating liver chemistries among patients with severe/critical illness versus mild cases of COVID-19 infection. Patients with severe/critical illness with COVID-19 infection have increased prevalence of coronary artery disease, cerebrovascular disease, and chronic obstructive pulmonary disease as compared with mild cases. A significant association between severe/critical COVID-19 infections with elevations in aspartate aminotransferase (pooled mean difference [MD], 11.70 U/L; 95% confidence interval [CI], 2.97, 20.43; P = 0.009), elevated total bilirubin (pooled MD, 0.14 mg/dL; 95% CI, 0.06, 0.22; P = 0.0005), and decreased albumin (pooled MD, −0.68 g/L; 95% CI, −0.81, −0.55; P < 0.00001) was noted. There was also a trend toward elevated alanine aminotransferase levels among these severe cases (pooled MD, 8.84 U/L; 95% CI, −2.28, 19.97; P = 0.12); however, this did not reach statistical significance. More severe/critically ill cases were associated with leukocytosis, neutrophilia, lymphopenia, elevated creatinine kinase, elevated lactate dehydrogenase (LDH), and elevated prothrombin time (PT). Conclusions: Comorbidities, including coronary artery disease, cerebrovascular disease and chronic obstructive pulmonary disease, are more prevalent in hospitalized Chinese patients with severe/critical illness from COVID-19, and these patients are more likely to manifest with abnormal liver chemistries. Further prospective studies are crucial to understand the pathophysiologic mechanisms underlying the hepatic manifestations of the novel COVID-19 infection and its clinical significance. © 2020 by the American Association for the Study of Liver Diseases.
Rights/Terms© 2020 by the American Association for the Study of Liver Diseases.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15496
- Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
- Authors: Fu Y, Zhu R, Bai T, Han P, He Q, Jing M, Xiong X, Zhao X, Quan R, Chen C, Zhang Y, Tao M, Yi J, Tian D, Yan W
- Issue date: 2021 Apr
- Liver Biochemistries in Hospitalized Patients With COVID-19.
- Authors: Bloom PP, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, Schaefer E, Chung RT
- Issue date: 2021 Mar
- SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
- Authors: Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J
- Issue date: 2020 Oct
- Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.
- Authors: Li J, He X, Yuan Yuan, Zhang W, Li X, Zhang Y, Li S, Guan C, Gao Z, Dong G
- Issue date: 2021 Jan
- Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis.
- Authors: Del Zompo F, De Siena M, Ianiro G, Gasbarrini A, Pompili M, Ponziani FR
- Issue date: 2020 Dec